1. Home
  2. HRMY vs PENN Comparison

HRMY vs PENN Comparison

Compare HRMY & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$31.05

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo PENN Entertainment Inc.

PENN

PENN Entertainment Inc.

HOLD

Current Price

$16.77

Market Cap

1.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
PENN
Founded
2017
1972
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
HRMY
PENN
Price
$31.05
$16.77
Analyst Decision
Buy
Buy
Analyst Count
9
13
Target Price
$44.11
$20.83
AVG Volume (30 Days)
793.3K
4.2M
Earning Date
05-07-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
N/A
EPS
2.71
N/A
Revenue
$868,453,000.00
$6,362,900,000.00
Revenue This Year
$19.75
$6.85
Revenue Next Year
$12.88
$3.83
P/E Ratio
$12.04
N/A
Revenue Growth
21.51
N/A
52 Week Low
$25.52
$11.65
52 Week High
$40.87
$20.61

Technical Indicators

Market Signals
Indicator
HRMY
PENN
Relative Strength Index (RSI) 51.87 55.09
Support Level $25.92 $16.60
Resistance Level $30.96 $18.13
Average True Range (ATR) 1.47 0.85
MACD 0.07 -0.07
Stochastic Oscillator 35.36 58.67

Price Performance

Historical Comparison
HRMY
PENN

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About PENN PENN Entertainment Inc.

Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.

Share on Social Networks: